FMC's Turnaround Playbook: India Exit Cleared, UK Herbicide Approved, but the Stock Still Can't Find a Floor

India's CCI approves FMC's $252M sale of FMC India to Crystal Crop Protection, as investors await Q3 results on October 29, 2026.

India's competition watchdog has waved through FMC Corporation's plan to offload its Indian subsidiary, removing a key regulatory hurdle from a divestment that will hand the agchem maker $252 million in proceeds. The Competition Commission of India approved the sale of FMC India Private Limited to Crystal Crop Protection, which is acquiring the business from FMC Netherlands Holdings II B.V. and affiliated entities.

The green light does not yet equal a closed deal, but it marks a meaningful step in management's effort to shed non-core operations and free up cash. Shareholders, however, greeted the news with a shrug. The stock changed hands at EUR 7.64, up 1.8% on the day, yet it remains 71% lower over the past twelve months — a decline that no single portfolio sale can reverse overnight.

A Busy Stretch of Corporate and Regulatory News

The India divestiture slots into a broader sequence of moves. Roughly two weeks ago, Belgium's Tessenderlo Group completed the purchase of a minority stake in FMC, a transaction that brings an industry partner into the shareholder base. Tessenderlo picked up about 20.0% of the company for approximately $403 million, funding part of the deal through multi-year loans from European banks and existing credit lines, according to media reports. Tessenderlo CEO Luc Tack has been nominated for a seat on FMC's board. Since the stake was disclosed, the shares have given up 12.6%.

On the product front, FMC is pushing hard on registrations. On September 28, the company secured UK regulatory clearance for its Koban herbicide, which contains 600 g/L pethoxamid and is aimed primarily at oilseed rape. The same day, FMC filed paperwork in Brazil for its Rimisoxafen active ingredient — the second worldwide dossier for the dual-mode-of-action herbicide, following a US submission in July. No Brazilian sales or use authorization exists yet, so the filing stands as a development milestone rather than a commercial launch.

Routine housekeeping has continued in parallel: Jacqueline Scanlan disposed of 5,137 shares to cover tax obligations, a standard insider transaction.

What Investors Are Actually Waiting For

None of these headlines has done much to lift sentiment at the trading desks. The market's attention is now fixed on FMC's third-quarter earnings, due after the US close on October 29, 2026, with a management call scheduled for October 30, 2026. Investors want hard evidence on the company's financial health and on demand trends — particularly whether the registration wins in crop protection are translating into the numbers, following a 52-week low of EUR 7.43.

The $252 million from the India sale should give FMC noticeably more financial breathing room. But the deal still has to close, and the new products still have to reach the market. Until both happen, the risks of a drawn-out restructuring remain front and center for anyone holding the stock.